PDCD1 and oropharynx squamous cell carcinoma: For this purpose, we used a melanoma cohort receiving PD-1 blockade therapy [42] and an HPV+ oropharyngeal squamous cell carcinoma (OPSCC) cohort [43] receiving standard-of-care therapy consisting of surgery, radiotherapy, chemotherapy or combinations of these modalities.